NasdaqGM:FMTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Forma Therapeutics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FMTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: FMTX's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

-11.0%

FMTX

-5.9%

US Biotechs

-3.4%

US Market


1 Year Return

n/a

FMTX

21.7%

US Biotechs

29.4%

US Market

Return vs Industry: Insufficient data to determine how FMTX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how FMTX performed against the US Market.


Shareholder returns

FMTXIndustryMarket
7 Day-11.0%-5.9%-3.4%
30 Day-8.0%-7.0%0.6%
90 Day-16.8%0.8%6.3%
1 Yearn/a23.5%21.7%32.2%29.4%
3 Yearn/a14.4%8.7%51.3%41.7%
5 Yearn/a51.4%40.3%119.6%95.2%

Long-Term Price Volatility Vs. Market

How volatile is Forma Therapeutics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Forma Therapeutics Holdings undervalued compared to its fair value and its price relative to the market?

3.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate FMTX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate FMTX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: FMTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: FMTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FMTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FMTX is good value based on its PB Ratio (3.8x) compared to the US Biotechs industry average (4.1x).


Next Steps

Future Growth

How is Forma Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-9.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FMTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FMTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FMTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FMTX's revenue (78.8% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: FMTX's revenue (78.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FMTX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Forma Therapeutics Holdings performed over the past 5 years?

-87.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: FMTX is currently unprofitable.

Growing Profit Margin: FMTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if FMTX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare FMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).


Return on Equity

High ROE: FMTX has a negative Return on Equity (-16%), as it is currently unprofitable.


Next Steps

Financial Health

How is Forma Therapeutics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: FMTX's short term assets ($415.7M) exceed its short term liabilities ($30.7M).

Long Term Liabilities: FMTX's short term assets ($415.7M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: FMTX is debt free.

Reducing Debt: FMTX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FMTX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: FMTX has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 22.8% each year.


Next Steps

Dividend

What is Forma Therapeutics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FMTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FMTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FMTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FMTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FMTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Frank Lee (53 yo)

2yrs

Tenure

US$3,571,642

Compensation

Mr. Frank D. Lee is Chief Executive Officer of FORMA Therapeutics, Inc. since March 27, 2019. Mr. Lee is President and Chief Executive Officer at Forma Therapeutics Holdings, Inc. since joining in March 27...


CEO Compensation Analysis

Compensation vs Market: Frank's total compensation ($USD3.57M) is about average for companies of similar size in the US market ($USD3.64M).

Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Frank Lee
President2yrsUS$3.57mno data
Mary Wadlinger
Senior VP of Corporate Affairs & Chief Human Resources Officer6.5yrsUS$944.89k0.24%
$ 4.2m
Todd Shegog
Senior VP & CFO1.5yrsno data0%
$ 0
David Cook
Senior VP & Chief Scientific Officer0.92yrno data0%
$ 0
Jeannette Potts
Senior VP1.5yrsno data0.0069%
$ 123.2k
Patrick Kelly
Senior VP & Chief Medical Officer1.58yrsno data0.088%
$ 1.6m
Andrew Littlehale
Treasurerno datano datano data

1.5yrs

Average Tenure

57.5yo

Average Age

Experienced Management: FMTX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Frank Lee
President2yrsUS$3.57mno data
Thomas Wiggans
Independent Non-Executive Director0.50yrno data0%
$ 0
Peter Wirth
Independent Non-Executive Chairman8.33yrsno data0.26%
$ 4.6m
Marsha Fanucci
Independent Non-Executive Director6.42yrsno data0.11%
$ 1.9m
Timothy Clackson
Independent Non-Executive Director3yrsno data0.048%
$ 854.8k
Peter Kolchinsky
Independent Non-Executive Director1.25yrsno data0%
$ 0
Wayne Frederick
Independent Non-Executive Director0.67yrno data0%
$ 0
Selwyn Vickers
Director0.17yrno datano data
Paolo Paoletti
Independent Non-Executive Director5.92yrsno data0.093%
$ 1.7m

2.1yrs

Average Tenure

60.5yo

Average Age

Experienced Board: FMTX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: FMTX only recently listed within the past 12 months.


Top Shareholders

Company Information

Forma Therapeutics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Forma Therapeutics Holdings, Inc.
  • Ticker: FMTX
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.772b
  • Shares outstanding: 48.91m
  • Website: https://www.formatherapeutics.com

Number of Employees


Location

  • Forma Therapeutics Holdings, Inc.
  • 500 Arsenal Street
  • Suite 100
  • Watertown
  • Massachusetts
  • 2472
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FMTXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2020

Biography

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers....


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/04 00:13
End of Day Share Price2021/03/03 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.